Makers Laboratories is a pharmaceutical company that built its name by making affordable generic medicines for India’s dispensing doctors and rural chemists, but its centre of gravity has shifted decisively - it now earns more than half its revenue from a chemical-manufacturing subsidiary it acquired in 2020, while its own factories are being retooled to supply injectables and eye drops to export markets under the brand of its much larger promoter-sibling, Ipca Laboratories. The recurring approach is to operate high-specification manufacturing assets - a modernised injectables unit, a sterile eye-drops plant, and a pyridine-chemicals factory - and then route their output through established partners rather than building a standalone sales engine from scratch. # Business segments Three engines at different stages - a chemical-manufacturing subsidiary that is now the group’s mainstay, a legacy generics business serving India’s dispensing-doctor channel, and an export-oriented sterile-manufacturing platform built on injectables and eye drops - all linked by a shared promoter group and a common go-to-market partner. ## 1. Chemical manufacturing: the group’s new centre of gravity **Resonance Specialties, a listed subsidiary acquired in 2020, makes pyridine-based drug intermediates and APIs for agrochemical and pharma customers - and it now generates more revenue than the rest of the group combined.** - **Acquired, not built** - Makers bought a 45.48% controlling stake in Resonance Specialties in late 2020 for about ₹224 crore in cash, gaining de-facto control and consolidating it as a subsidiary from December of that year. - **Pyridine is the platform** - the Tarapur factory in Maharashtra produces Pyridine, Picolines, Cynopyridines and their derivatives, which are intermediates and active ingredients (APIs) that go into agro-chemicals and pharmaceutical drugs. - **A separate listed entity** - Resonance is itself listed on the stock exchange, with non-controlling shareholders holding the remaining stake; its net assets attributable to outside investors stood at roughly ₹49.6 crore as of March 2026. ## 2. Generic formulations: the legacy dispensing-doctor franchise **Cheap, unbranded medicines sold through a four-zone field force to dispensing doctors, nursing homes and rural chemists - a business built on affordability rather than brand power.** - **Pioneer in a niche channel** - the company was an early mover in supplying generics directly to dispensing doctors, who give medicines to patients at the point of care rather than writing prescriptions for branded drugs. - **Cheaper than branded alternatives** - its products are priced below ethical (branded) formulations, which makes them particularly strong with doctors and chemists in rural areas where affordability drives purchasing decisions. - **Zonal field force, three depots** - the marketing network is split into four geographic zones (North, West, South, East), each with its own head and medical representatives who visit doctors and chemists; orders flow through stockists and distributors from three main depots in Mumbai, Ahmedabad and Ambala. - **Two ways to make a tablet** - some products are manufactured in-house under contract (loan-and-licence), while others are bought ready-made from third-party manufacturers and sold under a “manufactured by others, marketed by us” label. - **Sensitive to disease seasons** - growth slowed in FY 2025-26 because of a lower prevalence of acute diseases across the country, illustrating how the business depends on patient footfall rather than chronic-prescription refills. ## 3. Sterile manufacturing for export: injectables and eye drops **Two upgraded factories in Gujarat - one for liquid injectables, one for ophthalmic eye drops - being positioned for regulated export markets, with Ipca Laboratories as the marketing partner.** - **A ₹15-crore bet on eye drops** - a new sterile ophthalmic facility at Naroda, Ahmedabad, was commercialised in early 2021 and has since secured Eurasian Economic Union (EAEU) GMP certification, allowing it to file product dossiers in Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan. - **Injectables plant overhauled for global standards** - the older liquid-injectables unit on the same Naroda estate underwent an ₹11.2-crore modernisation, completed in mid-2022, funded by a rights issue that raised ₹14.75 crore; the goal is WHO-GMP certification so it can supply markets across the Rest of the World. - **Dossiers are the currency** - two ophthalmic formulation dossiers are already registered for the Eurasia market, with manufacturing for that region starting in late FY 2025-26, while more dossiers for both eye drops and injectables are under development or registration in other ROW countries. - **Ipca is the route to market** - the company’s major related-party transactions involve developing, registering, manufacturing and supplying both injectables and eye drops to Ipca Laboratories, which then sells and distributes them under its own brand name in India and ROW markets. # Group structure and partners **Makers Laboratories and its chemical subsidiary Resonance Specialties share a promoter group with the much larger Ipca Laboratories - and Ipca is simultaneously the group’s biggest customer, its brand-owner, and a related party that bought its office building.** - **Promoters sit across two listed companies** - the promoter group holds 58.78% of Makers and 36.73% of Ipca Laboratories; Makers itself holds a negligible 960 shares in Ipca, but the strategic link runs through common control, not equity. - **Ipca is the marketing engine** - Makers’ generic formulations, injectables and eye drops are all marketed under Ipca’s brand name in India and export markets, with related-party pricing done on a cost-plus-mark-up basis because regulatory approvals lock in manufacturing sources and make competitive bidding impractical. - **The office now belongs to Ipca** - in FY 2024-25, Makers sold its Kandivli office building (land plus a basement-and-three-storey structure) to Ipca Laboratories for ₹18.50 crore in cash, using the proceeds to repay borrowings and fund working capital. - **Resonance is consolidated but not wholly owned** - Makers holds 45.48% and exercises de-facto control, while non-controlling interests hold the remaining 54.52%; the subsidiary’s statutory auditor is a separate firm, Kailash Chand Jain & Co..